



5.21.086

| | | | |
|--------------------|-----------------------|------------------------------|-------------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | November 21, 2016 |
| Subject: | Nilandron | Page: | 1 of 5 |

Last Review Date: December 13, 2024

Nilandron

Description

Nilandron (nilutamide)

Background

Nilandron (nilutamide) is used as a combination agent with surgical castration for the treatment of metastatic prostate cancer. Nilandron is an orally active antiandrogen drug that works by blocking the effects of testosterone at the androgen receptor level thereby preventing an androgenic response. Nilandron interrupts the effect that testosterone has on the prostate and deprives it of signals typically responsible for growth and cell differentiation in the prostate (1).

Regulatory Status

FDA-approved indication: Nilandron is for use in combination with surgical castration for the treatment of metastatic prostate cancer. For maximum benefit, Nilandron treatment must begin on the same day as or on the day after surgical castration (1).

Nilandron is contraindicated in patients with severe hepatic impairment and patients should have a baseline liver enzymes test prior to initiation of therapy. Nilandron is also contraindicated in patients with severe respiratory insufficiency (1).

Nilandron carries a boxed warning for the risk of interstitial pneumonitis, which can lead to hospitalization and death (1).

It is not known whether Nilandron can cause fetal harm when administered to a pregnant woman (1).

| | | | |
|--------------------|-----------------------|------------------------------|-------------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | November 21, 2016 |
| Subject: | Nilandron | Page: | 2 of 5 |

Patients receiving Nilandron have reported a delay in adaptation to dark when passing from a lighted area to a dark area. Patients who experience this effect should be cautioned about driving at night or through tunnels (1).

The safety and effectiveness of Nilandron in pediatric patients less than 18 years of age have not been established (1).

Related policies

Erleada, Nubeqa, Orgovyx, Xtandi, Yonsa, Zytiga

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Nilandron may be considered **medically necessary** if the conditions indicated below are met.

Nilandron may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Gender Male

Diagnosis

Patient must have the following:

1. Metastatic prostate cancer

AND ALL of the following:

- a. Inadequate treatment response, intolerance, or contraindication to **ONE** of the following:
 - i. Generic nilutamide
 - ii. Bicalutamide
 - iii. Flutamide
- b. Baseline liver enzymes test with **NO** severe hepatic impairment
- c. Chest x-ray with **NO** severe respiratory insufficiency findings

| | | | |
|--------------------|-----------------------|------------------------------|-------------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | November 21, 2016 |
| Subject: | Nilandron | Page: | 3 of 5 |

- d. Used in combination with surgical castration
- e. **NO** dual therapy with another androgen receptor inhibitor (see Appendix 1)

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Gender Male

Diagnosis

Patient must have the following:

1. Metastatic prostate cancer

AND ALL of the following:

- a. **NO** severe respiratory insufficiency
- b. Prescriber agrees to monitor ALT and AST levels at regular intervals
- c. **NO** dual therapy with another androgen receptor inhibitor (see Appendix 1)

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Nilandron (nilutamide) is an orally active antiandrogen indicated for the treatment of metastatic prostate cancer with surgical castration. Nilandron is only indicated for use in men and should not be used in patients with severe respiratory insufficiency or in patients with a history of liver

| | | | |
|--------------------|-----------------------|------------------------------|-------------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2025 |
| Subsection: | Antineoplastic Agents | Original Policy Date: | November 21, 2016 |
| Subject: | Nilandron | Page: | 4 of 5 |

dysfunction or elevated liver enzymes. The safety and efficacy of Nilandron in pediatric patients less than 18 years of age have not been studied (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Nilandron while maintaining optimal therapeutic outcomes.

References

1. Nilandron [package insert]. St. Michael, Barbados: Concordia Pharmaceuticals Inc.; July 2022.
2. NCCN Drugs & Biologics Compendium® Nilutamide 2024. National Comprehensive Cancer Network, Inc. Accessed on October 3, 2024.

Policy History

| Date | Action |
|----------------|---|
| November 2016 | Addition to PA |
| March 2017 | Annual review |
| June 2017 | Annual review |
| June 2018 | Annual editorial review and reference update |
| September 2018 | Annual editorial review |
| June 2019 | Annual review |
| August 2019 | Addition of no dual therapy requirement and addition of Appendix 1 |
| September 2019 | Annual review and reference update |
| December 2019 | Annual review |
| June 2020 | Annual review |
| March 2021 | Annual editorial review and reference update |
| June 2021 | Annual review and reference update |
| September 2022 | Annual review and reference update |
| December 2022 | Annual review and reference update. Per SME, added precaution regarding delay in dark adaptation to regulatory status |
| September 2023 | Annual review and reference update |
| December 2023 | Annual review and reference update |
| March 2024 | Annual review and reference update |
| December 2024 | Annual review and reference update |

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 13, 2024 and is effective on January 1, 2025.

Section: Prescription Drugs **Effective Date:** January 1, 2025
Subsection: Antineoplastic Agents **Original Policy Date:** November 21, 2016
Subject: Nilandron **Page:** 5 of 5

Appendix 1 - List of Androgen Receptor Inhibitors

| Generic Name | Brand Name |
|-----------------------|------------|
| abiraterone | Yonsa |
| abiraterone | Zytiga |
| abiraterone/niraparib | Akeega |
| apalutamide | Erleada |
| darolutamide | Nubeqa |
| enzalutamide | Xtandi |
| nilutamide | Nilandron |